Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors.
Cell Therapeutics (NCM:CTIC) is +0.53 - +29.61% from the previous close of $1.79. It traded between $1.85 - 2.40 with total traded volume of 2157745 shares. Keep a close eye on CTIC, as the stock has been showing unusual moves over the past weeks. At Current market price, CTIC has recovered +31.07% from its 52-week Low of 1.77 and has Pulled back -71.88% from its 52-week high of 8.25.
This report is essential reading
for any serious investor, providing comprehensive financial information on a
company's performance, position and cash flows over the past 3 years,
includinginterim data. This information, extracted from reported financial
statements, forms the building blocks for any analysis undertaken by investment
professionals. - Key Stats and Ratios including; Valuation Ratios (e.g.
Price/Earnings), Per Share Data (e.g. EPS), Profitability Ratios (e.g. Gross
Margin), Management Effectiveness (e.g. Return on Equity), Financial Strength
(e.g. Quick Ratio) and Dividend Information (e.g. Dividend Yield). - 3 years of
history are available for most ratios (see above). - Share performance data and
12 month chart - Profit & Loss Account (3 years) - Balance sheet (3 years)
- Cash Flow Statement (3 years) - Educational content: Definitions of ratios
and guidance on using the data - Graphical analysis: All the key data in the
report is charted. Reuters Investment Profile reports are now available for
over 25,000 companies globally.Every report is updated weekly to ensure that
the information remains current.
